The global Veterinary Point-of-Care (PoC) Diagnostics Market size was estimated at USD 362 Mn in 2021, growing at a CAGR of 9.2% during the forecast period 2021-2027. This report gives a comprehensive outlook on veterinary Point-of-Care (PoC) diagnostics across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). This report gives historical, current, and future market sizes (US$ Mn) of product, application, sample, animal type, distribution channel and geographic regions. Veterinary hospitals are prime channel for Point-of-Care (PoC) systems distribution across the globe. Based on product, diagnostic test kits market is growing at highest CAGR over the forecast period. This report studies veterinary Point-of-Care (PoC) diagnostics market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the market report includes regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the report include suppliers, manufacturers, The global impact of COVID-19, marketers, policymakers engaged in the manufacturing and supply of veterinary Point-of-Care (PoC) diagnostics.
Key Market Developments:
In September 2020, Zoetis announced the launch of Vetscan Imagyst™, a diagnostic platform that uses a combination of image recognition technology, algorithms and cloud-based artificial intelligence (AI) to deliver accurate testing results to the clinic. Imagyst’s first indication will be for testing fecal samples for parasites, and it has the potential for broader applications to different types of testing in the future. Imagyst was developed to first help veterinarians make accurate and timely point-of-care intestinal parasitic diagnoses for dogs and cats.
In March 2022, VolitionRx Limited (Volition), a multinational epigenetic company announced that it has signed an exclusive global supply and license agreement with Heska Corporation (Heska)—a global provider of advanced veterinary diagnostics. Through the new agreement, Heska will receive exclusive worldwide rights to sell Volition’s Nu.Q Vet Cancer Screening test. Heska, a company dedicated to developing the next generation of rapid, highly affordable, point-of-care diagnostics for companion animals